 |
 |
INSP 平台技術 INSP Platform Technology
Innovative Nanocapsule derived from Sulphated Polysaccharide Platform - INSP003
INSP 為一種創新奈米膠囊技術，打造具標靶性、高穩定性、高效率、安全性地遞送多種藥物，目前INSP003為包覆紫杉醇的次世代精準標靶化療藥物 ，進一步優化療效與安全性。
INSP is an innovative nanocapsule technology designed to enable targeted, highly stable, efficient, and safe delivery of a wide range of therapeutic agents. INSP003, a next-generation precision targeted chemotherapy, encapsulates Docetaxel to further optimize therapeutic efficacy while enhancing safety.
一、核心結構與功能 Core Structure and Functions
1.高分子穩定層 Polymeric Stabilizing Layer
■ 提供結構與介面穩定性
Provides structural and interfacial stability
■ 增強藥物包覆效率
Enhances drug encapsulation efficiency
■ 可控制藥物釋放行為
Enables controlled drug release behavior
2. Fucoidan（伏剋藻）核心 Fucoidan Core
■ 具 CD62P（P-selectin）標靶能力
Exhibits targeting capability toward CD62P (P-selectin)
■ 高生物相容性
High biocompatibility
■ 有助於腫瘤與發炎微環境的精準定位
Facilitates precise localization to tumor and inflammatory microenvironments
3.可載運藥物類型 Types of Therapeutic Cargo
■ 化療小分子藥物
Small-molecule chemotherapeutic drugs
■ 胜肽類藥物
Peptide-based drugs
■ 蛋白質藥物
Protein therapeutics drugs
■ 核酸類藥物
Nucleic acid-based drugs
4.整體優勢總結 Summary of Overall Advantages
■ 多元藥物相容性高
High compatibility with diverse drug modalities
■ 具主動標靶能力（CD62P）
Active targeting capability via CD62P (P-selectin)
■ 提升藥物穩定性與安全性
Enhanced drug stability and safety
■ 適用於次世代精準治療平台
Applicable as a next-generation precision-medicine platform
二、新一代藥物：INSP003腫瘤標靶性奈米紫杉醇
Next Generation: INSP003 Tumor-Targeted Nano-Docetaxel
1.核心優勢 Core Advantages：
■ 腫瘤標靶能力更強
Stronger tumor-targeting capability
■ 顯著提升安全性
Significantly improved safety profile
■ 具克服抗藥性潛力
Potential to overcome drug resistance
2.定位 Positioning：
進一步優化療效與安全性的次世代精準標靶化療藥物
A next-generation precision targeted chemotherapeutic drug designed to further optimize both efficacy and safety.
3.說明 Description：
INSP003 以奈米載體技術為核心，在既有紫杉醇療效基礎上，同步強化腫瘤標靶性與安全性，具備成為第三代紫杉醇藥物的潛力。
INSP003 is built on an advanced nanocarrier platform and leverages the established therapeutic efficacy of Docetaxel while simultaneously enhancing tumor-targeting specificity and safety, demonstrating strong potential as a third-generation Docetaxel therapy.
三、第一代：小分子紫杉醇 First Generation: Small-Molecule Paclitaxel/Docetaxel
代表藥物 Representative drugs：
太平洋紫杉醇、歐洲紫杉醇
Paclitaxel、Docetaxel
限制 Limitations：
溶劑毒性高、非專一性分佈、副作用明顯
High solvent-related toxicity, Non-specific systemic distribution, Pronounced adverse effects
四、第二代：奈米藥物(白蛋白結合) Second Generation: Nanomedicine (Albumin-Bound)
1.代表藥物 Representative drugs ：
白蛋白紫杉醇
Abraxane
2. 限制 Limitations：
非專一性分佈
Non-specific systemic distribution
Innovative Nanocapsule derived from Sulphated Polysaccharide Platform - INSP003
INSP 為一種創新奈米膠囊技術，打造具標靶性、高穩定性、高效率、安全性地遞送多種藥物，目前INSP003為包覆紫杉醇的次世代精準標靶化療藥物 ，進一步優化療效與安全性。
INSP is an innovative nanocapsule technology designed to enable targeted, highly stable, efficient, and safe delivery of a wide range of therapeutic agents. INSP003, a next-generation precision targeted chemotherapy, encapsulates Docetaxel to further optimize therapeutic efficacy while enhancing safety.
一、核心結構與功能 Core Structure and Functions
1.高分子穩定層 Polymeric Stabilizing Layer
■ 提供結構與介面穩定性
Provides structural and interfacial stability
■ 增強藥物包覆效率
Enhances drug encapsulation efficiency
■ 可控制藥物釋放行為
Enables controlled drug release behavior
2. Fucoidan（伏剋藻）核心 Fucoidan Core
■ 具 CD62P（P-selectin）標靶能力
Exhibits targeting capability toward CD62P (P-selectin)
■ 高生物相容性
High biocompatibility
■ 有助於腫瘤與發炎微環境的精準定位
Facilitates precise localization to tumor and inflammatory microenvironments
3.可載運藥物類型 Types of Therapeutic Cargo
■ 化療小分子藥物
Small-molecule chemotherapeutic drugs
■ 胜肽類藥物
Peptide-based drugs
■ 蛋白質藥物
Protein therapeutics drugs
■ 核酸類藥物
Nucleic acid-based drugs
4.整體優勢總結 Summary of Overall Advantages
■ 多元藥物相容性高
High compatibility with diverse drug modalities
■ 具主動標靶能力（CD62P）
Active targeting capability via CD62P (P-selectin)
■ 提升藥物穩定性與安全性
Enhanced drug stability and safety
■ 適用於次世代精準治療平台
Applicable as a next-generation precision-medicine platform
二、新一代藥物：INSP003腫瘤標靶性奈米紫杉醇
Next Generation: INSP003 Tumor-Targeted Nano-Docetaxel
1.核心優勢 Core Advantages：
■ 腫瘤標靶能力更強
Stronger tumor-targeting capability
■ 顯著提升安全性
Significantly improved safety profile
■ 具克服抗藥性潛力
Potential to overcome drug resistance
2.定位 Positioning：
進一步優化療效與安全性的次世代精準標靶化療藥物
A next-generation precision targeted chemotherapeutic drug designed to further optimize both efficacy and safety.
3.說明 Description：
INSP003 以奈米載體技術為核心，在既有紫杉醇療效基礎上，同步強化腫瘤標靶性與安全性，具備成為第三代紫杉醇藥物的潛力。
INSP003 is built on an advanced nanocarrier platform and leverages the established therapeutic efficacy of Docetaxel while simultaneously enhancing tumor-targeting specificity and safety, demonstrating strong potential as a third-generation Docetaxel therapy.
三、第一代：小分子紫杉醇 First Generation: Small-Molecule Paclitaxel/Docetaxel
代表藥物 Representative drugs：
太平洋紫杉醇、歐洲紫杉醇
Paclitaxel、Docetaxel
限制 Limitations：
溶劑毒性高、非專一性分佈、副作用明顯
High solvent-related toxicity, Non-specific systemic distribution, Pronounced adverse effects
四、第二代：奈米藥物(白蛋白結合) Second Generation: Nanomedicine (Albumin-Bound)
1.代表藥物 Representative drugs ：
白蛋白紫杉醇
Abraxane
2. 限制 Limitations：
非專一性分佈
Non-specific systemic distribution